Acetamoren vs MK-677

Acetamoren wins for: reportedly cleaner appetite modulation, less reported water retention, and potentially longer effective duration—but with limited direct data, most claims are based on class effects and user reports rather than hard studies.

MK-677 wins for: robust, published pharmacology; repeatable results for IGF-1, fat-free mass, and sleep quality; well-characterized dose response; and wide community experience. It's the reference model for orally administered secretagogues.

Pick Acetamoren if:

• A smoother, less aggressive appetite increase is needed (for adherence on a cut or appetite-prone users).
• Lower risk of water retention or edema is a must.
• An all-in-one GHSR agonist is desired, but the preference is to avoid the strong hunger spikes seen with classic MK-677 protocols.
• Research entails a newer molecule with anecdotal reports of improved tolerability.
• Sourcing is available from a reputable lab with batch testing results.

Pick MK-677 if:

• Maximal reliability and proven efficacy are top priorities (published, peer-reviewed trials on dosing, results, and side effect profile).
• IGF-1 and fat-free mass are the main endpoints being tracked.
• Long-term or multi-cycle protocols are on the table (as tachyphylaxis is not seen over 24 months).
• Appetite surge is actually desired (hard gainers, lean-bulking phases).
• Safety data and pharmacokinetics are non-negotiable for the research plan.